Results 61 to 70 of about 2,896 (157)
Bruton tyrosine kinase (BTK) inhibitor Zanubrutinib shows considerable potential for treating activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL). However, its efficacy is often limited by unresolved resistance mechanisms.
Zhuojun Liu +9 more
doaj +1 more source
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp +5 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Association between patient-reported symptoms and clinical outcomes in R/R CLL
: The ALPINE trial was a randomized, open-label study comparing the efficacy and safety of zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Using patient-
Timothy Victor +9 more
doaj +1 more source
ABSTRACT Brain metastases (BMs) represent a major clinical challenge due to their high incidence in cancers such as non‐small cell lung cancer (NSCLC) and breast cancer, and the limited efficacy of systemic therapies resulting from inadequate drug penetration across the blood–brain barrier.
Yuqian Zhao, Weize Huang
wiley +1 more source
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK.
Robert Roskoski, Jr
doaj +1 more source
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study
: Some patients with chronic lymphocytic leukemia who develop progressive disease (PD) during covalent Bruton tyrosine kinase (BTK) inhibitor treatment acquire resistance mutations in BTK or PLCG2.
Jennifer R. Brown +12 more
doaj +1 more source
Zanubrutinib in the treatment of Waldenström Macroglobulinemia
Waldenström Macroglobulinemia (WM) is an uncommon malignancy of IgM-secreting lymphoplasmacytic cells. The spectrum of acquired somatic mutations is heterogeneous, with MYD88 mutations occurring in more than 90%. Recurrent mutations in CXCR4, KMT2D, ARID1A, TERT, and TP53 are also detected, with some of these impacting prognosis or treatment response ...
Elizabeth Goodall, Stephen Opat
openaire +3 more sources

